[go: up one dir, main page]

SE9401709D0 - Improved alphavirus vectors for expression of heterologous DNA - Google Patents

Improved alphavirus vectors for expression of heterologous DNA

Info

Publication number
SE9401709D0
SE9401709D0 SE9401709A SE9401709A SE9401709D0 SE 9401709 D0 SE9401709 D0 SE 9401709D0 SE 9401709 A SE9401709 A SE 9401709A SE 9401709 A SE9401709 A SE 9401709A SE 9401709 D0 SE9401709 D0 SE 9401709D0
Authority
SE
Sweden
Prior art keywords
expression
alphavirus
heterologous dna
vectors
alphavirus vectors
Prior art date
Application number
SE9401709A
Other languages
English (en)
Inventor
Mathilda Sjoeberg
Maarit Suomalainen
Henrik Garoff
Original Assignee
Mathilda Sjoeberg
Maarit Suomalainen
Henrik Garoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mathilda Sjoeberg, Maarit Suomalainen, Henrik Garoff filed Critical Mathilda Sjoeberg
Priority to SE9401709A priority Critical patent/SE9401709D0/sv
Publication of SE9401709D0 publication Critical patent/SE9401709D0/sv
Priority to AT95920347T priority patent/ATE352633T1/de
Priority to JP52958095A priority patent/JP3786956B2/ja
Priority to CA002188421A priority patent/CA2188421A1/en
Priority to AU25826/95A priority patent/AU698976B2/en
Priority to EP95920347A priority patent/EP0760000B1/en
Priority to US08/737,608 priority patent/US6224879B1/en
Priority to PCT/SE1995/000558 priority patent/WO1995031565A1/en
Priority to DE69535376T priority patent/DE69535376T2/de
Priority to FI964577A priority patent/FI964577A0/sv
Priority to US09/657,312 priority patent/US6692750B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
SE9401709A 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA SE9401709D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA
DE69535376T DE69535376T2 (de) 1994-05-18 1995-05-17 Expressionsvektor des alphavirus
AU25826/95A AU698976B2 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
JP52958095A JP3786956B2 (ja) 1994-05-18 1995-05-17 アルファウイルス発現ベクター
CA002188421A CA2188421A1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
AT95920347T ATE352633T1 (de) 1994-05-18 1995-05-17 Expressionsvektor des alphavirus
EP95920347A EP0760000B1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
US08/737,608 US6224879B1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
PCT/SE1995/000558 WO1995031565A1 (en) 1994-05-18 1995-05-17 Alphavirus expression vector
FI964577A FI964577A0 (sv) 1994-05-18 1996-11-15 Alfavirusuttryckningsvektor
US09/657,312 US6692750B1 (en) 1994-05-18 2000-09-07 Alphavirus expression vector

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA

Publications (1)

Publication Number Publication Date
SE9401709D0 true SE9401709D0 (sv) 1994-05-18

Family

ID=20394041

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9401709A SE9401709D0 (sv) 1994-05-18 1994-05-18 Improved alphavirus vectors for expression of heterologous DNA

Country Status (10)

Country Link
US (2) US6224879B1 (sv)
EP (1) EP0760000B1 (sv)
JP (1) JP3786956B2 (sv)
AT (1) ATE352633T1 (sv)
AU (1) AU698976B2 (sv)
CA (1) CA2188421A1 (sv)
DE (1) DE69535376T2 (sv)
FI (1) FI964577A0 (sv)
SE (1) SE9401709D0 (sv)
WO (1) WO1995031565A1 (sv)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6458560B1 (en) 1996-04-05 2002-10-01 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
JP2001501483A (ja) * 1996-10-10 2001-02-06 ガロフ，ヘンリク アルファウイルス―レトロウイルスベクター
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU741747B2 (en) 1997-05-13 2001-12-06 University Of North Carolina At Chapel Hill, The Lentivirus-based gene transfer vectors
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
ATE391726T1 (de) 1999-10-22 2008-04-15 Sanofi Pasteur Ltd Modifiziertes gp100 und dessen verwendung
DE60124899T2 (de) 2000-05-10 2007-08-16 Sanofi Pasteur Ltd., Toronto Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
CA2410948C (en) 2000-05-31 2012-07-17 Chiron Corporation Method for the purification of alphavirus replicon particles
US6783939B2 (en) 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
WO2002020721A2 (en) 2000-09-07 2002-03-14 University Of North Carolina At Chapel Hill Vectors derived from south african arbovirus no. 86
JP4394878B2 (ja) 2000-12-08 2010-01-06 ライフ テクノロジーズ コーポレーション 複数の認識部位を用いた核酸分子合成のための方法および組成物
ATE485059T1 (de) * 2001-03-27 2010-11-15 Univ New York Tumortherapie mit vektoren auf sindbis virus- basis
CA2460269C (en) 2001-09-06 2013-01-15 Alphavax, Inc. Alphavirus replicon vector systems
WO2003085087A2 (en) 2002-04-09 2003-10-16 Aventis Pasteur, Limited Modified cea nucleic acid and expression vectors
US6899507B2 (en) * 2002-02-08 2005-05-31 Asm Japan K.K. Semiconductor processing apparatus comprising chamber partitioned into reaction and transfer sections
EP1386926A1 (en) * 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
US20040208848A1 (en) * 2002-12-13 2004-10-21 Smith Jonathan F. Multi-antigenic alphavirus replicon particles and methods
NZ540657A (en) 2002-12-13 2006-09-29 Alphavax Inc High-yielding, GMP-compatible, commercially feasible process for producing highly purified alphavirus replicon particle (ARP) preparations for use in human and veterinary medicine
AU2004204456A1 (en) * 2003-01-09 2004-07-29 Invitrogen Corporation Cellular delivery and activation polypeptide-nucleic acid complexes
WO2004085660A2 (en) * 2003-03-20 2004-10-07 Alphavax, Inc. Improved alphavirus replicons and helper constructs
ES2327643T3 (es) 2003-07-11 2009-11-02 Alphavax, Inc. Vacunas contra citomegalovirus basadas en alfavirus.
US7910093B2 (en) 2003-08-19 2011-03-22 New York University Method for detecting cancer cells and monitoring cancer therapy
KR101162970B1 (ko) * 2003-10-08 2012-07-12 테리온 바이오로직스, 인크. 변형된 ｃｅａ/ｂ7 벡터
EP1745074A2 (en) * 2004-04-29 2007-01-24 The University of North Carolina at Chapel Hill Methods and compositions for enhancing cell adhesion properties
WO2005113782A1 (en) 2004-05-18 2005-12-01 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
AU2006302794B2 (en) * 2005-02-15 2011-08-04 Children's Hospital, Inc. New live virus vaccines
US7303898B2 (en) * 2005-03-29 2007-12-04 New York University Defective sindbis viral vectors
WO2008030220A2 (en) * 2005-08-11 2008-03-13 The Board Of Regents Of The University Of Texas System Chikungunya virus infectious clones and uses thereof
US20100322951A1 (en) * 2006-12-29 2010-12-23 Bacilligen, Inc. Replication-proficient dsRNA capsids and uses thereof
US8460913B2 (en) 2007-06-21 2013-06-11 Alpha Vax, Inc. Promoterless cassettes for expression of alpha virus structural proteins
AU2009248735B2 (en) * 2008-05-23 2015-08-20 Fit Biotech Oy Expression vector encoding alphavirus replicase and the use thereof as immunological adjuvant
EP3443107A1 (en) 2016-04-13 2019-02-20 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
BR112019007433A2 (pt) 2016-10-17 2019-07-02 Synthetic Genomics Inc sistemas de replicon de vírus recombinante e usos dos mesmos
CN110352247B (zh) * 2016-12-05 2024-06-28 杨森制药公司 用于增强基因表达的组合物和方法
EA202091517A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
EA202091516A1 (ru) 2017-12-19 2020-11-03 Янссен Сайенсиз Айрлэнд Анлимитед Компани Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
US11021692B2 (en) 2017-12-19 2021-06-01 Janssen Sciences Ireland Unlimited Company Hepatitis B virus (HBV) vaccines and uses thereof
JP7494117B2 (ja) 2018-01-19 2024-06-03 ヤンセン ファーマシューティカルズ，インコーポレーテッド 組換えレプリコン系を使用する免疫応答の誘導および増強
CN119351425A (zh) * 2024-12-23 2025-01-24 上海奥浦迈生物科技股份有限公司 具有增强外源基因表达水平的核酸分子及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091309A (en) 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
GB9406498D0 (en) 1994-03-31 1994-05-25 Smithkline Beecham Biolog Novel compounds

Also Published As

Publication number Publication date
EP0760000A1 (en) 1997-03-05
AU2582695A (en) 1995-12-05
US6692750B1 (en) 2004-02-17
WO1995031565A1 (en) 1995-11-23
EP0760000B1 (en) 2007-01-24
JP3786956B2 (ja) 2006-06-21
ATE352633T1 (de) 2007-02-15
US6224879B1 (en) 2001-05-01
AU698976B2 (en) 1998-11-12
DE69535376T2 (de) 2007-11-08
CA2188421A1 (en) 1995-11-23
JPH10500017A (ja) 1998-01-06
DE69535376D1 (de) 2007-03-15
FI964577A (sv) 1996-11-15
FI964577A0 (sv) 1996-11-15

Similar Documents

Publication Publication Date Title
SE9401709D0 (sv) Improved alphavirus vectors for expression of heterologous DNA
AU2155795A (en) Alphavirus cdna vectors
DE69637660D1 (de) Verfahren zür einführung und expression von genen in tierischen zellen
FR2681786B1 (sv)
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
GR3035050T3 (en) Method of preparing a viral vector by homologous intermolecular recombination
HK1024714A1 (en) Dumbbell expression constructs for gene therapy
BR9913331A (pt) Expressão e exportação de inibidores de angiogênese como imunofusinas
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
IL122120A (en) Recombinant mva virus containing a foreign gene inserted in a naturally occuring deletion within the genome
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
DK0998568T3 (da) Mutant med uracil phosphoribosyltransferaseaktivitet
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
NO864990D0 (no) Solubilisering av proteinaggregater.
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
EP0804613A4 (en) TUMOR SUPPRESSORGENES, PROTEINS CODED BY THEM AND THE USE OF SUCH GENES AND PROTEINS
BR9811096A (pt) Sequências, moléculas, vetores e vacinas de dna recombinante para doença do calcivìrus felino e processo para a produção e o uso dos mesmos
EP0462836A3 (en) Recombinant vector plasmid capable of expressing human manganese superoxide dismutase, and process of producing this enzyme
ATE162853T1 (de) Menschlicher rekombinanter plazentaler ribonuklease-inhibitor und verfahren zur herstellung
PL291700A1 (en) Method of retarding expression of a gen present in a plant genome, dna sequence, protein able to cause such retardation, expression case, bacterial transforming vector, bacterial cells, transformed plant cells, culture of maize cells or tissue and transformed maize plant
HUP0202722A2 (hu) Szekvencia-specifikus DNS-rekombináció eukarióta sejtekben
ATE59204T1 (de) Verfahren zum einbringen von klonierten amplifizierbaren genen in eukaryotische zellen und zur herstellung von proteinprodukten.
PL344766A1 (en) Recombined dna sequence, vector incorporating such recombined dna sequence, proteins obtained by expression of that recombined dna sequence and micro-organism's or plant's cell or their protoplasts transformed by that recombined dna sequence